Video
Dr. Lorenza Rimassa on Tivantinib for EGFR Inhibitor-Resistant mCRC
Author(s):
Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).
Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).
The study looked at tivantinib in Combination with cetuximab in EGFR inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) mCRC.
In the first stage of the study, three out of the 21 patients enrolled had an objective response and eight had stable disease. These results are exciting because all of the patients enrolled in the study had already become resistant to all of the treatment available, said Rimassa.
A phase II study with 41 patients has just completed enrollment. Results are expected at the end of the year.
